Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Biomolecules · 19.09.2025 · 15 (9) · 1342
DOI: 10.3390/biom15091342 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 19.09.2025. Verfasst von Pasqual Llongueras-Espí und 3 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Heart Failure and Heart Transplant Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona…. Hauptthemen laut MEDLINE: Heart Failure, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes and obesity due to their metabolic benefits. Beyond weight loss and glycemic control, emerging evidence suggests they may also exert cardioprotective effects. In the context of heart failure (HF), particularly HF with preserved ejection fraction (HFpEF), GLP-1RAs have been associated with improvement in symptoms, physical capacity, biomarkers, and structural cardiac remodeling. These benefits appear to be independent of weight loss, suggesting additional mechanisms including anti-inflammatory effects, improved myocardial metabolism or modulation of epicardial adipose tissue. However, current data largely come from non-HF dedicated trials, with limited standardization of the HF phenotype. Results are overall inconsistent and may suggest potential harm in some cases, particularly in HF with reduced ejection fraction (HFrEF). This review aims to summarize the current evidence on the role of GLP-1RAs in heart failure, explore possible underlying mechanisms and highlight key gaps in knowledge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Heart Failure and Heart Transplant Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
- Biomedical Research Networking Center on Cardiovascular Diseases (CIBER-CV), Carlos III Health Institute, 28029 Madrid, Spain.
- Community Heart Failure Program, Cardiology and Internal Medicine Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
- Department of Clinical Sciences, School of Medicine, University of Barcelona, 08036 Barcelona, Spain.
ORCID-Profile: Pasqual Llongueras-Espí, Elena García-Romero, Josep Comín-Colet, José González-Costello
Zitieren
APA
Llongueras-Espí, P., García-Romero, E., Comín-Colet, J., & González-Costello, J. (2025). Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure. Biomolecules, 15(9), 1342. https://doi.org/10.3390/biom15091342
Vancouver
Llongueras-Espí P, García-Romero E, Comín-Colet J, González-Costello J. Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure. Biomolecules. 2025;15(9):1342. doi:10.3390/biom15091342
BibTeX
@article{LlonguerasEsp2025,
author = {Llongueras-Espí, Pasqual and García-Romero, Elena and Comín-Colet, Josep and González-Costello, José},
title = {Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {9},
pages = {1342},
doi = {10.3390/biom15091342}
}
EUVIMED